Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care

NCT05257031 | Completed Phase 3

• 1 other identifier: SKNt-002-CP3
• Study Type: interventional
• Target: 56
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this clinical trial is to assess the efficacy and safety of the investigational product SmofKabiven extra Nitrogen in patients requiring parenteral nutrition (PN) to achieve the target protein dose. The cumulative target protein dose is 6.2 g per kg of body weight (BW) over the five study treatment days, with 1.0 g/kg BW on Study Day 1 and 1.3 g/kg BW per day on Study Days 2-5; the target caloric intake is 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2-5, following the recommendation of the ESPEN guideline on clinical nutrition in the intensive care unit 2019 regarding a slow-ramp up of calories during the first week of critical illness.

Conditions

Nutrition Therapy; Critical Illness

Outcome Measures

Primary Outcomes (1)

• Protein intake during the study treatment period

  Percentage of patients who have reached ≥ 70% of the cumulative target protein intake.

  Study Days 1 to 5

Secondary Outcomes (5)

• Percentage of the cumulative target protein intake reached over the study treatment period

  Study Days 1 to 5

• Mean daily protein intake from parenteral nutrition (PN), enteral nutrition (EN), oral nutrition (ON), oral nutrition supplements (ONS) over the study treatment period

  Study Days 1 to 5

• Cumulative protein intake from PN, EN, ON, ONS over the study treatment period

  Study Days 1 to 5

• Mean daily caloric intake from PN, EN, ON, ONS, and non-nutritional sources over the study treatment period

  Study Days 1 to 5

• Cumulative caloric intake from PN, EN, ON, ONS, and non-nutritional sources over the study treatment period

  Study Days 1 to 5

Other Outcomes (9)

• Incidence of adverse events

  Until 24 hours after the end of last infusion

• Incidence of serious adverse events

  Until 24 hours after the end of last infusion

• Changes in vital signs (blood pressure)

  Study Days 1 to 6

Study Arms (1)

SmofKabiven extra Nitrogen

EXPERIMENTAL

The investigational product will be administered in a volume that provides the target caloric intake of 15 kcal/kg BW on Study Day 1 and 20 kcal/kg BW/day on Study Days 2 to 5. If calories are provided from other sources (e.g., enteral/oral nutrition/oral nutritional supplements or non-nutritional sources including glucose solution for drug dilution or propofol), the dose of the investigational product will be reduced accordingly to avoid calorie overload above the respective daily caloric targets.

Drug: SmofKabiven extra Nitrogen

Interventions

SmofKabiven extra Nitrogen DRUG

SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.

SmofKabiven extra Nitrogen

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years and \< 90 years, male or female
• Critically ill, medical or surgical intensive care unit (ICU) patient
• The patient was admitted to the ICU during the previous 24-48 hours and has a minimum expected ICU stay of 5 days after the completion of screening
• Central venous access available for continuous infusion of the investigational product
• Contraindication against EN or limited tolerance to EN; it is planned that the patient receives ≥75% of the total target caloric intake from PN during the 5 investigational product treatment days
• Informed consent (signed and dated) from the patient to participate in this clinical trial. If the patient is unable to make a decision because of his/her critical condition, a decision regarding study enrolment is made at a case conference involving three physicians

You may not qualify if:

• Contraindication against PN or inability to receive PN via central venous access
• The patient has received PN within the last 7 days before the start of screening
• Body mass index (BMI) \<18.5 kg/m2 or \>35 kg/m2
• Any severe, persistent blood coagulation disorder with uncontrolled bleeding
• Any congenital errors of amino acid metabolism
• Uncontrolled hyperglycaemia despite insulin treatment
• Known hypersensitivity to fish, egg, soybean proteins, peanut proteins, or to any of the active ingredients or excipients contained in SmofKabiven extra Nitrogen
• General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, and decompensated cardiac insufficiency
• Severe renal insufficiency defined by the following criteria:
• serum creatinine level \> 353.6 µmol/L, or
• creatinine level ≥ 3.0 times higher than the upper limit of normal (according to the KDIGO 2012 Clinical Practice Guideline), or
• diuresis \< 0.3 mL/kg/hr during ≥ 12 hrs (Acute Kidney Injury stage ≥ 3 according to the KDIGO 2012 Clinical Practice Guideline) without access to renal replacement therapy
• Unstable haemodynamic conditions (e.g., acute myocardial infarction, stroke, embolism, severe sepsis, shock) including acute shock (arterial serum lactate \> 2.0 mmol/L)
• Severe liver insufficiency
• Haemophagocytic syndrome

Sponsors & Collaborators

• Fresenius Kabi: lead

Study Sites (1)

Municipal Clinical Hospital No. 40 of Moscow Healthcare Department

Moscow, Russia

Location

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Denis N Protsenko, MD

  Municipal Clinical Hospital No. 40 of Moscow Healthcare Department

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2022
• First Posted: February 25, 2022
• Study Start: February 12, 2022
• Primary Completion: September 11, 2022
• Study Completion: June 30, 2023
• Last Updated: February 21, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

RU (1)